文献速递白血病造血干细胞移植与细胞治疗

抗CD19 CAR-T桥接异基因造血干细胞移植治疗复发难治B-ALL

Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
PubMed 文献 · Am J Hematol · 2019-08-02

该非随机干预性实用性临床试验探讨CAR-T后巩固性allo-HSCT能否改善MRD阴性完全缓解患者的长期预后。58例复发难治B-ALL患者接受CAR-T治疗,51例(87.9%)达完全缓解;47例MRD阴性完全缓解患者中21例自愿接受allo-HSCT。两组总生存无差异,但在高移植前骨髓流式MRD≥5%或具有不良预后标志物的亚组中,allo-HSCT显著延长无事件生存和无复发生存。

要点

  • 58例复发难治B-ALL接受CAR-T,51例(87.9%)达完全缓解。
  • MRD阴性完全缓解患者中,allo-HSCT组与未移植组总生存无差异。
  • 高移植前BM-FCM-MRD或不良预后标志物者,allo-HSCT显著延长EFS和RFS。

核心结论

  • CAR-T桥接allo-HSCT是复发难治B-ALL安全有效的治疗策略,可能延长无事件生存和无复发生存,尤其在高移植前BM-FCM-MRD或具有不良预后标志物的患者中。

研究设计与样本

  • 非随机干预性实用性临床试验,第一阶段58例复发难治B-ALL患者接受淋巴细胞清除化疗后分次输注CAR-T细胞;第二阶段47例无既往allo-HSCT且无禁忌或不限的MRD阴性完全缓解患者中,21例自愿在CAR-T后三个月内接受巩固性allo-HSCT。

主要发现

  • 第一阶段58例中51例(87.9%)达完全缓解。
  • MRD阴性完全缓解患者中,接受allo-HSCT者与未接受者的总生存无差异。
  • 在高移植前BM-FCM-MRD(≥5%)或具有不良预后标志物的亚组中,allo-HSCT显著延长无事件生存和无复发生存(P < .05)。
  • 在移植前BM-FCM-MRD <5%且无不良预后标志物的患者中,allo-HSCT与未移植的无事件生存和无复发生存无差异(P > .05)。

临床怎么用

  • CAR-T治疗后达MRD阴性完全缓解的复发难治B-ALL患者,可考虑桥接allo-HSCT以改善无事件生存和无复发生存,尤其在高移植前BM-FCM-MRD或具有不良预后标志物者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor-modified T-cell (CAR-T) therapy is effective and safe for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), but its value has been limited in terms of long-term leukemia-free survival. New strategies that can help CAR-T therapy achieve lasting effect are urgently warranted. This non-randomized interventional pragmatic clinical trial had a particular aim. It explored whether consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT) could improve the long-term prognosis of the minimal residual disease-negative complete remission (MRD- CR) patients after CAR-T therapy. In the first stage, 58 r/r B-ALL patients received split doses of CAR-T cells after lymphodepleting chemotherapy, and 51 (87.9%) achieved CR. In the second stage, 21/47 MRD- CR patients without previous allo-HSCT and contraindications or other restrictions, on their own accord, received consolidative allo-HSCT within three months after CAR-T therapy. There was no difference in overall survival (OS) between the MRD- CR patients who received allo-HSCT and those who did not. However, event-free survival (EFS) and relapse-free survival (RFS) were significantly prolonged by allo-HSCT in the subgroups. This was with either high (≥5%) pre-infusion bone marrow MRD assessed by flow cytometry (BM-FCM-MRD) or poor prognostic markers (P < .05). However, no difference was found in EFS and RFS for patients with pre-infusion BM-FCM-MRD <5% and without poor prognostic markers (P > .05). To conclude, CAR-T therapy bridging to allo-HSCT is a safe and effective therapeutic strategy for r/r B-ALL patients, and may prolong their EFS and RFS, especially when they have high pre-infusion BM-FCM-MRD or poor prognostic markers.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jiang H, Li C, Yin P, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol. 2019. PMID: 31321805. doi:10.1002/ajh.25582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。